Transcriptional Biomarkers for Triple-Negative Breast Cancer Identification ID: 2023-035
This study identifies and validates transcriptional biomarkers for improved detection and diagnosis of triple-negative breast cancer (TNBC).
Photo by SewcreamStudio - stock.adobe.com
Technology Overview
The research undertakes a comprehensive meta-analysis of RNA-sequencing samples from ten independent studies to discover universal and subtype-specific biomarkers for TNBC. It addresses sample diversity challenges and underrepresentation of certain TNBC subtypes, achieving high specificity and sensitivity in biomarker prediction.
Key Advantages
- High predictive capability with combined specificity and sensitivity of 98
- 9%Identification of both universal and subtype-specific biomarkers for TNBCDiscovery of novel differentially expressed genes alongside known TNBC-related genes
- Enhanced understanding of TNBC's molecular pathology through gene product and pathway analysis
- Potential for more rapid and accurate TNBC diagnostics
Problems Addressed
- Underrepresentation and diversity challenges in TNBC subtype samples
- Lack of specificity in existing TNBC diagnostic methods
- Insufficient understanding of the molecular mechanisms underlying TNBC
Market Applications
- Development of diagnostic tests for TNBC detection and subtype identification
- Targeted therapy development based on identified biomarkers
- Personalized medicine approaches for TNBC treatment
- Research tools for further study of TNBC and other cancer types
Additional Information
Technology ID: 2023-035
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report